US EditionWeekly roundup: From BIO 2025 to building boards – Optimum Strategic CommunicationsLink to: Hot topic: Should we keep renaming diseases?Scroll to top
Summary by Optimum Strategic Communications
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Weekly roundup: From BIO 2025 to building boards – Optimum Strategic CommunicationsLink to: Hot topic: Should we keep renaming diseases?Scroll to top
Rewind Therapeutics strengthens scientific advisory board with leading international neurology experts as it advances its first-in-class remyelination therapy Rewind Therapeutics, which is developing first-in-class treatments for demyelination-associated diseases, has appointed four internationally recognised innovators in neurology – Professors Shiv Saidha, Cristina Granziera, David Leppert, and Roberto Furlan – to its Scientific Advisory Boa…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium